Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Return on Capital Employed for 8 consecutive years, with 0.89% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed fell 74.0% year-over-year to 0.89%, compared with a TTM value of 0.89% through Sep 2025, down 74.0%, and an annual FY2024 reading of 0.32%, up 52.0% over the prior year.
  • Return on Capital Employed was 0.89% for Q3 2025 at X4 Pharmaceuticals, up from 1.12% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.08% in Q1 2025 and bottomed at 1.33% in Q3 2022.
  • Average Return on Capital Employed over 5 years is 0.72%, with a median of 0.78% recorded in 2023.
  • Peak annual rise in Return on Capital Employed hit 101bps in 2025, while the deepest fall reached -98bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.81% in 2021, then increased by 4bps to 0.78% in 2022, then decreased by 0bps to 0.78% in 2023, then soared by 64bps to 0.28% in 2024, then tumbled by -217bps to 0.89% in 2025.
  • Business Quant data shows Return on Capital Employed for XFOR at 0.89% in Q3 2025, 1.12% in Q2 2025, and 0.08% in Q1 2025.